Publications by authors named "J Bagel"
Background: In the primary analysis of a phase 3b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe plaque psoriasis affecting the scalp (NCT03897088), tildrakizumab, an anti-interleukin-23 p19 antibody, met the primary efficacy endpoint at week 16.
Objective: To evaluate maintenance of tildrakizumab efficacy and safety for the treatment of scalp psoriasis from the week 52 full analysis.
Methods: Patients randomized to tildrakizumab continued receiving tildrakizumab 100 mg every 12 weeks; patients randomized to placebo (analyzed separately) switched to tildrakizumab 100 mg at week 16.
Article Synopsis
- Moderate-to-severe atopic dermatitis (AD) significantly affects patients' quality of life, and advanced systemic therapeutics (AST) like dupilumab and upadacitinib are available but underutilized.
- A study of 3,076 patients in the U.S. found that 436 were eligible for AST treatment, and factors like private insurance and disease severity influenced their treatment initiation.
- Despite the availability of AST, many patients—47% of adolescents and 58% of adults—remain untreated, highlighting a need for greater advocacy and accessibility for those with severe AD.
Background: More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin-23 receptor signaling, versus placebo (PBO) at week (W)16 of the phase 2 FRONTIER-1 study.
Objective: FRONTIER-2, a long-term extension of FRONTIER-1, evaluated JNJ-77242113 through 1 year.
Methods: FRONTIER-1 participants received JNJ-77242113 at doses from 25 mg daily to 100 mg twice daily or PBO through W16.
Article Synopsis
- The study compares the effectiveness of home-based vs. office-based phototherapy for psoriasis, highlighting that while office therapy is cost-effective, it’s often hard to access compared to the more patient-preferred home therapy, which lacks sufficient clinical data, especially for those with darker skin.
- Conducted across 42 dermatology practices in the US, the trial involved 783 participants aged 12 and older with psoriasis, who were randomly assigned to either home or office phototherapy for 12 weeks, followed by another 12 weeks of observation.
- Results showed that home phototherapy led to better skin clearance and quality of life improvements, with 32.8% of participants achieving clear skin compared to
Introduction: Due to variable psoriasis symptoms, disease progression, and individual responses to therapy, patients may start, stop, or switch biologic therapies. Real-world data on the associated disease burden of patients with psoriasis who do and do not switch biologics are incomplete.
Methods: This study compared disease burden among patients from the CorEvitas Psoriasis Registry (July 2017-December 2021) who switched biologics and those who did not within 4-12 months following initiation.